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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The objective of this review is to estimate the accuracy of the conventional oral examination (COE) used singly or in combination with
another index test (Additional Table 1) as a screening test for the detection of oral cancer and potentially malignant disorders (PMD)
of the lip and oral cavity of apparently healthy adults.
The secondary objective of this review is to estimate the accuracy of the different tests with COE, when compared with each other.
We will use meta-regression to explore possible sources of heterogeneity, ways in which the observed diagnostic test accuracy varies
according to particular characteristics. Covariates to be included in these analyses will include.
• Characteristics of the study sample: prevalence of carcinoma or PMD disease in the study (> 50% prevalence), inclusion of HPV
+ adults, tobacco users / high alcohol consumption.
• Target condition (oral squamous cell carcinoma alone or oral squamous cell carcinoma and PMD).
• Attributes of the screening programme: prospective organised or opportunistic, type of reference standard (examination and
clinical evaluation by physician with specialist knowledge or extended follow-up), operator (dental or general practice professionals or
other healthcare workers).
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B A C K G R O U N D
Target condition being diagnosed
The target conditions of interest are oral squamous cell carcinoma
(OSCC), the most common form of oral cavity cancer (Scully
2000a), and potentiallymalignant disorders (PMD), of the lip and
oral cavity in apparently healthy adults. At a meeting of interna-
tional oral cancer and precancer experts held in 2005, the concept
of precancer, along with issues surrounding classification and def-
inition, aetiology, diagnosis and management was extensively dis-
cussed. Through consensus, the term ’potentially malignant dis-
orders’ was selected to convey the fact that not all precancerous
lesions and conditions will transform to cancer, but rather that
there is the potential for malignant transformation (van der Waal
2009; Warnakulasuriya 2007).
The natural history of oral cancer is not fully understood, given
variations in disease processes and dysplastic changes in PMD
(Napier 2008; Scully 2009). Most oral carcinomas are preceded
by PMD of which erythroplakia, non-homogeneous leukoplakia,
erosive lichen planus, oral submucous fibrosis and actinic ker-
atosis are perhaps the most important (Warnakulasuriya 2007).
The concept of a two-step process of cancer development of the
oral mucosa (i.e. precursor to established lesion) is established.
Oral leukoplakia is the best-known precursor lesion and between
< 1% and 18% develop into oral cancer. The original 1978 World
Health Organization (WHO) definition of oral leukoplakia has
been revised to read “The term leukoplakia should be used to rec-
ognize white plaques of questionable risk having excluded (other)
known diseases or disorders that carry no increased risk for cancer”
(Warnakulasuriya 2007). The presence of epithelial dysplasia can
help predictmalignant development but the diagnosis is essentially
subjective, with not all lesions exhibiting dysplasia, some becom-
ing malignant and some regressing. Carcinoma can also develop
from lesions in which epithelial dysplasia was not previously di-
agnosed. Numerous attempts have been made to relate biological
characteristics to themalignant potential of leukoplakias, but find-
ing a definitive characteristic remains elusive (Reibel 2003). Most
authorities regard leukoplakia as a dynamic rather than a static pro-
cess, in terms of its progression and the development ofmalignancy
(Napier 2008). For example, Jaber et al (Jaber 2003) followed up
630 patients who attended oral medicine clinics in London and
Bristol between 1972 and 1996. The majority of oral leukoplakia
(43.8%) had features of mild dysplasia, 30%moderate and 24.7%
severe oral epithelial dysplasia. Whilst this is strongly suggestive
that dysplasia is typically associated with oral leukoplakia, it can
also be seen in patients with reactive epithelial changes such as
candidosis, viral infections, lichen planus, and denture-induced
hyperplasia. The study concluded that predicting the severity of
histopathological change from clinical examination alone remains
difficult. Estimates of malignant transformation rates (MTR) vary
enormously, from site to site within the mouth, from population
to population and from study to study (Napier 2008). The MTR
of hospital-based surveys are consistently higher than community-
based studies because of sampling bias. Petti (Petti 2003) calcu-
lated a global MTR of oral leukoplakia of 1.36% per year (95%
confidence interval (CI) 0.69% to 2.03%) based on the prevalence
of leukoplakia, but this far exceeds the numbers of actual cases of
malignancy. Virtually all studies emphasize the chronicity of oral
PMD, with an increasing tendency to malignant change in the
first 5 years. For example, the incidence of OSCC arising from
leukoplakia in Californians was greatest in the second year of fol-
low-up (11 out of 45; 24%) (Silverman 1984). The proportion of
PMD that will developOSCC is uncertain but low; best estimates
suggest a rate of less than 2% per annum (Napier 2008).
The early detection and excision of some PMD can prevent ma-
lignancy, or if malignancy is detected, there is some evidence
that appropriate treatment can reduce disease severity and im-
prove survival rates (Brocklehurst 2010b; van der Waal 2009;
Warnakulasuriya 2007). Leukoplakias can be treated by a num-
ber of methods. According to Lodi et al’s systematic review (Lodi
2006), the effectiveness of surgical interventions, including laser
therapy and cryotherapy, has not been studied by means of a ran-
domised controlled trial (RCT) with a no treatment/placebo arm.
VitaminA and retinoids have been tested by five RCTs, two studies
investigated beta carotene or carotenoids, the other drugs tested
were bleomycin (one study), mixed tea (one study) and ketorolac
(one study). None of the treatments tested showed a benefit when
compared with the placebo. Lodi et al concluded that there was no
evidence of effective treatment in preventing the malignant trans-
formation of leukoplakia.Where resolution of a lesion is observed,
relapses and adverse effects are common.
Technologies to treat and manage oral cancer have progressed sub-
stantially, as shown by systematic reviews of RCT of interventions,
e.g. Bessell 2011; Furness 2011; Glenny 2010. Once progressed
to frank malignancy, traditional treatment is surgery and radio-
therapy. More recently, systemic chemotherapy has been included
as part of the treatment regimen before or during radiotherapy.
Surgery for the treatment of oral cancer is followed by exacting
reconstructive surgery to restore form and function. Debilitating
side effects can occur as a result of radiotherapy and chemother-
apy, adversely affecting an individual’s quality of life. The 5-year
survival following diagnosis has remained at around 50% for the
past 30 years in most countries (Parkin 2001; Warnakulasuriya
2009). This is in marked contrast to the improved survival rates
in many other cancers, such as those of the breast and the colon
(Cancer Research UK), but may be explained at least in some part
by the fact that oral cancer is more often diagnosed at a late stage
of the disease, when prognosis is poorer and the risks of significant
morbidity and mortality are substantially higher (Rogers 2009;
Rusthoven 2010).
Index test(s)
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The standard screening of apparently healthy adults for oral can-
cer and PMD is a systematic and thorough visual inspection and
examination of the oral mucosa and palpation of the neck under
normal (incandescent) light. In most instances this is carried out
by a frontline clinician such as a general dentist. This conventional
visual and tactile oral examination (COE) used as a screen can be
conducted with theminimum of effort and distress to the individ-
ual (Additional Table 1). Screening can be carried out opportunis-
tically, for instance when an individual presents to their dentist for
a check-up, or as part of an organised screening programme.The
COE is usually followed by referral for further investigation if this
is deemed necessary. The form of further investigation is variable
nationally or internationally, with different investigational path-
ways. For instance this could take the form of examination by an
oral medicine specialist or specialist oral surgeon at a specialist
clinic or hospital facility.
Reviews of primary studies of diagnostic test accuracy in this area
have identified a number of index tests which could be used as
adjuncts to the COE to improve earlier detection of oral cavity
cancer and PMD (Fedele 2009; Leston 2010; Lingen 2008; Patton
2008; Rethman 2010). These include:
• vital staining (Toluidine Blue, Tolonium chloride)
• light-based detection (such as ViziLite and ViziLite Plus,
Microlux/DL, VELscope, Orascoptic DK, Identafi 3000)
• blood and saliva analysis.
Vital staining andoral cytology are long available adjuncts to a con-
ventional oral examination (Leston 2010; Lingen 2008). Other
tests such as light-based detection systems have become commer-
cially available only more recently. Blood analysis and saliva anal-
ysis are more novel tests at an early stage of evaluation.
Of the index tests listed above, vital staining, light-based detection
and blood and saliva analysis could be used as screening adjuncts to
the COE (Additional Table 1). In this review, we will restrict vital
staining index tests to those applied in a rinse form. A companion
review (Diagnostic tests for oral cancer and potentially malignant
disorders in patients presenting with clinically evident lesions) will
restrict vital staining index tests to those applied to a lesion that
has been visualized. Where access to general dental practitioners
or general practitioners is limited, either as a result of geographical
location or barriers to uptake of healthcare provision, screening
using the index tests listed above could, in principle, be undertaken
by trained healthcare workers.
It is worth noting there are regional differences in regulations on
the use of some of the above tests. For example, Toluidine Blue
having been consistently rejected as a stand alone technique, is
not cleared to be a stand alone screening technique in the United
States. It is included in the ViziLite Plus system. However, the
Toluidine Blue only component is approved by the US Food and
Drug Administration (FDA) as a marking device.
Of the index tests listed above, all have the potential to be used as
adjuncts to theCOE (Additional Table 1) by healthcare workers or
clinicians undertaking screening in the general population. Adding
any one of the proposed index tests to the COE, the tests could
have a triage role in detecting lesions of uncertain significance
with referral where appropriate. For instance, traumatic keratoses
are common, and referring each patient with a white patch to
a specialist to undergo a scalpel biopsy is excessive, and incurs
increased financial cost and patient worry. A non-invasive index
test or combination of tests adjunctive to the COE that provides a
frontline clinician with a high degree of accuracy would not only
reduce the number of patients with benign disease being referred,
but could avoid the need for invasive biopsy in patients testing
negative.
Rationale
Oral cancer is a significant global health problem with increas-
ing incidence and mortality rates (Ferlay 2010; Warnakulasuriya
2009). Cancer of the lip or oral cavity is a relatively common can-
cer worldwide, with an estimated 263,000 new cases and 127,000
deaths in 2008, and an increasing incidence in recent years (Ferlay
2010). There is wide geographic variation in disease incidence
and mortality, with almost double the incidence in developing
countries as in developed countries, and a threefold increase in
mortality. Tobacco use, alcohol consumption, betel quid chewing
and low socio-economic status have traditionally been thought to
be the most important risk factors of oral cancer (Conway 2008;
Faggiano 1997; La Vecchia 1997;Macfarlane 1995; Ogden 2005).
The human papillomavirus (HPV) is also an important risk factor
in oral squamous cell carcinoma and there is some evidence that
HPV positive cancers associate with better survival (Ang 2010).
Men have had a higher incidence of oral cancer than women
(Ferlay 2010), but this disparity can be explained by men having
a higher exposure to the above risk factors (Freedman 2007). The
gender difference has narrowed in recent decades from a ratio of 5
males to 1 female diagnosed with oral cancers in the 1960s to less
than 2 to 1 in 2008 (Ferlay 2010). Although traditionally the risk
of oral cancer increases with age, the incidence among younger
adults has been increasing in the European Union and the United
States (Warnakulasuriya 2009). The 5-year survival rate depends
on multiple factors, including patient and tumour characteristics,
treatment received and stage at diagnosis. Oral cancer incidence
and mortality can be reduced using three approaches: (i) primary
prevention, (ii) secondary prevention, screening and early detec-
tion, and (iii) improved treatment (Scully 2000b).
Successful early detection of oral cancer or PMD is highly depen-
dent onwhether ’at risk’ individuals present for screening examina-
tion. Early diagnosis relies on the awareness and motivation of the
clinician or patient in identifying a suspicious lesion or symptom
while it is still at an early stage. Whilst many organisations advo-
cate cancer-related checks, including the AmericanCancer Society
for individuals of all risk groups (American Cancer Society 1992)
and the US Preventive Health Services Task Force for high risk in-
dividuals (US Preventive Services Task Force), there ismuch global
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variation in the provision and promotion of routine oral cancer
examinations. Currently, no national population-based screening
programmes for oral cancer have been implemented in the devel-
oped countries, although opportunistic screening has been advo-
cated (Brocklehurst 2010a).Consequently, individuals will often
present for examination at a later stage of the disease, when the risks
of significant morbidity and mortality are substantially higher. A
province-wide programme is being evaluated in British Columbia,
Canada (Rosin 2006) but the evaluation is ongoing and no final
results have been reported to date. Brocklehurst et al’s systematic
review identified only one RCT using visual examination with a
follow-up period of 9 years which was carried out in India. The
authors of the review concluded that the current evidence is insuf-
ficient to recommend population-based screening and suggested
that opportunistic screening of high risk groups may potentially
improve outcomes (Brocklehurst 2010a).
There is some debate in the literature on anticipated differences in
diagnostic accuracy of prospective population-based invitational
screening programmes and a more opportunistic approach (when
patients attend their general (dental) practitioner for routine ex-
amination or for treatment). In Downer et al’s systematic review
of test performance in screening for oral cancer and PMD, only
prospective investigations of population screening with specified
reference standards were included. The pooled sensitivities and
specificities were 0.85 (95% CI 0.730 to 0.919) and 0.97 (95%
CI 0.930 to 0.982) respectively (Downer 2004). An opportunistic
approach that focuses on high risk groups is also possible (McGurk
2010; Sankaranarayanan 1997). A simulation study which used
neural network and machine learning techniques suggested op-
portunistic screening aimed at high risk groups may be both ef-
fective and cost effective (Speight 2006). However, the results of
the only completed randomised controlled trial undertaken on
oral cancer screening as an intervention demonstrated that the
yield from both whole population and opportunistic approaches
is likely to be important (Brocklehurst 2010a). Many individu-
als with risk factors may not attend the dentist and are therefore
not amenable to an opportunistic approach (Netuveli 2006; Yusof
2006). Furthermore, the evidence suggests that diagnostic/screen-
ing tools based onmachine learning such as Speight et al’s (Speight
2006) can provide useful but preliminary evidence, as they tend
to be limited by “the fitting of models that are implausible and the
tendency ... to understate misclassification errors” (Liu 2006).
Reviews assessing the test accuracy of a conventional oral exami-
nation as a population screening tool (e.g. Downer 2004; Moles
2002) have highlighted methodological flaws in the primary di-
agnostic test accuracy studies, although explicit methodological
quality assessment of these studies using a validated and widely
used checklist was not undertaken.
In this review we aim to identify screening tests for oral cancer
and PMD to evaluate the diagnostic accuracy of the COE and
the accuracy of the other index tests (Additional Table 1) used
as adjuncts to the oral examination in apparently healthy adults.
The index tests proposed for evaluation in this review are suitable
for use in the community or as part of a dental examination in a
general dental practitioners’ office. The review will include both
prospective investigations of organised screening programmes and
prospective opportunistic screening. It is important that this re-
view consider both, as opportunistic screening of patients attend-
ing in a general practice setting are self selecting and may not
be representative of the population of interest. In either scenario,
screening may be carried out by dental professionals or healthcare
workers. The purpose of the screening is to identify the presence
or absence of PMDs which require referral to secondary care for
definitive diagnosis and possibly treatment. The proposed index
tests cannot confirm whether a PMD is cancerous before deciding
on referral to secondary care; biopsy with histopathology is cur-
rently the only confirmatory method of oral cancer diagnosis.
The Cochrane Oral Health Group has undertaken a number of
intervention reviews in the field of treatment of oral and oropha-
ryngeal cancers (Bessell 2011; Furness 2011; Glenny 2010) and
screening programmes for the early detection and prevention of
oral cancer (Brocklehurst 2010a). This screening test accuracy re-
view will complement the intervention reviews.
O B J E C T I V E S
The objective of this review is to estimate the accuracy of the con-
ventional oral examination (COE) used singly or in combination
with another index test (Additional Table 1) as a screening test for
the detection of oral cancer and potentially malignant disorders
(PMD) of the lip and oral cavity of apparently healthy adults.
Secondary objectives
The secondary objective of this review is to estimate the accuracy
of the different tests with COE, when compared with each other.
Investigation of sources of heterogeneity
We will use meta-regression to explore possible sources of hetero-
geneity, ways in which the observed diagnostic test accuracy varies
according to particular characteristics. Covariates to be included
in these analyses will include.
• Characteristics of the study sample: prevalence of carcinoma
or PMD disease in the study (> 50% prevalence), inclusion of
HPV + adults, tobacco users / high alcohol consumption.
• Target condition (oral squamous cell carcinoma alone or
oral squamous cell carcinoma and PMD).
• Attributes of the screening programme: prospective
organised or opportunistic, type of reference standard
(examination and clinical evaluation by physician with specialist
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knowledge or extended follow-up), operator (dental or general
practice professionals or other healthcare workers).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Studies of clinical cohorts of apparently healthy adults which re-
port the diagnostic accuracy of the conventional oral examination
(COE) used singly or in combination with an index test listed
in Additional Table 1, for oral cancer and potentially malignant
disorders (PMD) with respect to one of the reference standards.
These will include cross-sectional studies (or consecutive series)
and randomised controlled trials (RCTs) of test accuracy. We will
exclude case series and case control studies which can lead to in-
flated estimates of prevalence and test accuracy (Whiting 2004).
We will exclude studies reported in abstract form alone, uncon-
trolled reports and randomised controlled trials of the effective-
ness of screening programmes (intervention studies). Where ran-
domised or paired comparative designs are available these will be
included in the review and analysed separately. Studies should re-
port data for true positives, false positives, true negatives and false
negatives for each test. Only studies reporting results at an indi-
vidual level (as opposed to a lesion level) will be included.
Participants
Apparently healthy adults (aged 16 years or over) attending an
organised screening programme or screened during attendance at
a dental or general practice examination.
Index tests
TheCOE used as a screen, alone or in combination with any other
screening tests previously listed (Additional Table 1). The COE
(comparator test) is the initial point of the screen, which all adults
will receive. The index test will be used as an adjunct following the
COE irrespective of whether oral cancer or PMD is suspected by
the COE alone (i.e. a positive test result is a positive result from
either the COE or the index test or both).
Comparator tests
The comparator test is the COE used as a stand alone screen
as previously described. This is the standard screen commonly
used in clinical practice, although problems with its use have been
identified (Lingen 2008).
Target conditions
Following the consensus views of the expert working group of the
WHO Collaborating Centre for Oral Cancer and Precancer, the
target conditions of the lip or oral cavity of interest are noted as:
Carcinoma
• Squamous cell carcinoma
Potentially malignant disorders
• Leukoplakia
• Erythroplakia
• Lichen planus
• Lupus erythematosus
• Submucous fibrosis
• Actinic keratosis
• Hereditary disorders such as dyskeratosis congenita or
epidermolysis bullosa.
Reference standards
The reference standard is examination and clinical evaluation by a
physician with specialist knowledge, such as an oral andmaxillofa-
cial pathologist or oral medicine specialist, working to the current
diagnostic guidelines of their locality. We will include the diag-
nostic protocol / guidelines used in each study in the ’Character-
istics of included studies’ table. Studies with confirmatory biopsy
of individuals who screened negative by the index test may exist,
but are questionable ethically (Downer 2004). Confirmation of
individuals screened negative by an index test may be done by
extended follow-up of a minimum of 5 years.
Search methods for identification of studies
Electronic searches
The following databases will be searched using a highly sensitive
search strategy:
• Cochrane Oral Health Group’s Trials Register (to present)
• Cochrane Register of Diagnostic Test Accuracy Studies (to
present)
• MEDLINE (1948 to present)
• EMBASE (1980 to present)
• MEDION (2003 to present).
The MEDLINE search strategy outlined in Appendix 1 will be
modified for the listed databases.The search will not be limited by
language or publication status. Non-English articles will be trans-
lated, unless a translator cannot be found through The Cochrane
Collaboration.
The search strategy has been constructed in accordance with this
protocol and that of a companionCochraneDiagnostic Test Accu-
racy review ’Diagnostic tests for oral cancer in patients presenting
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with clinically suspicious lesions’ being undertaken concurrently
by the same review team.
Searching other resources
Wewill also search relevant conference proceedings.We will locate
further studies through citation searches and reference lists of key
articles, and by contacting authors of identified articles to request
information of any unpublished or ongoing studies.
Data collection and analysis
Selection of studies
Titles and abstracts of all articles identified from the searcheswill be
independently assessed by two review authors (TanyaWalsh (TW)
and Joseph Liu (JL)). For articles that appear to meet the inclusion
criteria, or where a clear decision cannot be made from scanning
the title and abstract alone, full reports will be obtained. Two
review authors (TW and JL) will independently assess each report
for inclusion. Where disagreements occur, the review authors will
attempt to resolve these by discussion. If needed, a third review
author (Paul Brocklehurst (PB)) will be asked to help resolve the
discrepancies in consultation with the other two review authors.
Data extraction and management
Two review authors (TW and JL) will independently extract data
using a piloted data collection form.Discrepancies will be resolved
through discussion. If an agreement cannot be reached, a third
review author will be consulted (PB). Study authors will be con-
tacted to obtain relevant missing data if these are not available in
the printed report.
The following data will be recorded from each study.
• Sample characteristics (age, sex, socio-economic status, risk
factors (e.g. HPV status, prevalence of tobacco use and alcohol
consumption), number of participants / lesions, lesion site)
• Setting (country, disease prevalence, type of screening)
• The type of index test(s) used (category, name, positivity
threshold)
• Study information (design, reference standard, case
definition, training and calibration of personnel)
• Study results (true positive, true negative, false positive,
false negative, any equivocal results, withdrawal).
Assessment of methodological quality
The revised QUADAS tool, QUADAS-2 (Whiting 2011) will be
used to assess the quality of the primary diagnostic studies over
four key domains: patient selection, index test, reference standard
and flow and timing of participants through the study.
In the first phase of the tool, the review question will be stated
in terms of patient sample, index test, reference standard and tar-
get condition. This information is detailed in the Criteria for
considering studies for this review section of this protocol. In phase
two, the QUADAS-2 tool will be tailored to use with this re-
view (Additional Table 2). Review specific guidance will be used
to facilitate documentation of the pertinent descriptive informa-
tion contained in the primary studies. Customised instructions to
aid judgement of the signalling questions will be given (following
Patton 2008). Two core signalling questions were removed: ’Was a
case-control design avoided?’ (this study design was excluded from
the review); ’Did all patients receive a reference standard?’ (this
was a criterion for inclusion). Three additional signalling items
relating to commercial funding, training and calibration and mul-
tiple index tests have been added to the core signalling questions.
In phase three, a flow diagram will be drawn. In the final phase, an
overall judgement of risk of bias and applicability is to be under-
taken. A risk of bias judgement (’high’, ’low’ or ’unclear’) will be
reached for each domain. If the answers to all signalling questions
within a domain are judged as ’yes’ indicating low risk of bias, then
the domain will be judged to be at low risk of bias. If any signalling
question within a domain is judged as ’no’ indicating high risk
of bias then this indicates that potential bias exists. This will be
followed by a judgement for concerns regarding applicability for
the patient selection, index test and reference standard domains.
We will pilot the use of the QUADAS-2 tool independently on
five study reports. Where disagreements occur between the two
review authors the review specific descriptions will be clarified
until consistency is obtained.
Results of the quality assessment for all included studies will be
summarised in a narrative report. A summary tabular presentation
of the results for each domain will be also provided separately
for risk of bias and concerns regarding applicability, along with a
graphical display summarising this information.
Statistical analysis and data synthesis
Data for the true positive, true negative, false positive and false
negative values for each test in each study will be tabulated. For
each index test, estimates of diagnostic accuracy as sensitivity and
specificity along with their 95% confidence intervals will be dis-
played as coupled forest plots, and plotted in receiver operating
characteristic (ROC) space.
Meta-analysis will be used to combine the results of studies for each
index test. Random-effects models will be used. If however there
are too few studies to reliably estimate between study variability
then fixed-effect models will be used. The statistical software SAS
will be used throughout (SAS Institute Inc., Cary, USA).
Classification of responses of the various tests are given in Addi-
tional Table 1.Where a common threshold of response is reported,
the analysis will estimate the expected values of sensitivity and
specificity (Bivariate approach Reitsma 2005). Where there is a
variation in thresholds, the expected hierarchical summary ROC
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curve for the tests across different thresholds will be estimated
(Macaskill 2010; Rutter 2001). Hierarchical SROC curves will be
fitted using the Proc NLMixed procedure in SAS. The proposed
analysis is subject to change based on information reported in the
primary studies. For example, if there is little variation in the pos-
itive thresholds of the blood and salivary index tests, it will not be
appropriate to attempt to fit a summary ROC curve (Macaskill
2010). Where the primary studies have published more than one
threshold result, accuracy estimates will be reported for all the
thresholds. Data from all thresholds will be extracted and used in
the analysis.
The statistical analysis plan can be specified as follows.
Primary analyses: The primary analyses will compare the COE
used singly or in combination with any other test (Additional
Table 1) with the reference standard.
• COE
• COE with vital rinse
• COE with light detection
• COE with blood / salivary analysis.
This will either estimate the average sensitivity and specificity of a
test or describe the variation in sensitivity and specificity at differ-
ent thresholds by estimating a hierarchical summary ROC curve,
depending on nature of the index tests. Parameter estimates will
include sensitivity, specificity and their correlation or hierarchical
summary ROC curve.
Secondary analysis: The comparative accuracy of the index tests
with the reference standard will be the focus of the secondary anal-
yses. A preliminary analysis will graphically display the sensitivities
and specificities of the index tests. This will be followed by a series
of indirect pairwise analyses and structured as follows.
• COE versus COE with vital rinse
• COE versus COE with light detection
• COE versus COE with blood / salivary analysis
• COE with vital rinse versus COE with light detection
• COE with vital rinse versus COE with blood / salivary
analysis
• COE with light detection versus COE with blood / salivary
analysis.
All studies will be included in each pairwise comparison. Where
studies of direct comparisons exist (i.e. paired data from all patients
or randomising individuals to different tests) the results of these
studies will be analysed and reported separately.
Themethodology used is akin to the investigation of heterogeneity
(as below) i.e. adding a covariate for test type into the Bivariate or
Hierarchical SROC analysis.
Investigations of heterogeneity
Meta-regression analyses will be carried out to explore possible
sources of heterogeneity. Covariates to be included in these anal-
yses will include characteristics of the study sample (prevalence of
carcinoma or PMD in the study (> 50% prevalence), inclusion of
HPV + adults, tobacco users / high alcohol consumption); target
condition (oral squamous cell carcinoma alone or oral squamous
cell carcinoma and PMD); aspects of study design (prospective
organised or opportunistic); type of reference standard (examina-
tion and clinical evaluation by physician with specialist knowledge
or extended follow-up) and operator (dental or general practice
professionals or other healthcare workers). Different thresholds of
binary categorisations will also be considered.
The log likelihood of models including the covariate will be com-
pared to those models without the covariate. Formal model com-
parisons of either the Hierarchical SROC or Bivariate models will
be undertaken using the Likelihood Ratio statistic to statistically
compare the effects of adding or removing covariates. If statistical
evidence of heterogeneity is found further investigations will be
undertaken.
Sensitivity analyses
Sensitivity analyses will be conducted. This will entail restricting
the analysis to studies where the reference standard is examination
and clinical evaluation by physician with specialist knowledge or
where differential verification is avoided.
Assessment of reporting bias
Tests for reporting bias will not be conducted because current tests
are misleading when applied to systematic reviews of diagnostic
test accuracy (Leeflang 2008; Tang 2000).
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A D D I T I O N A L T A B L E S
Table 1. Screening tests for PMDs and oral cavity cancer
Test Characteristics Classification of response Other information
Conventional oral examination
(COE).
A standard visual and tactile
examination of the oral mu-
cosa under normal (incandes-
cent) light
The presence of an oral mu-
cosal abnormality is classified as
a positive test result; the absence
of any oral mucosal abnormali-
ties is classified as a negative test
result
Traditionally been used as an
oral cancer screen, but its utility
is debated (Lingen 2008).
Advantages: quick and easy
once trained, minimally inva-
sive.
Disadvantages: oral mucosal
abnormalities are not necessar-
ily clinically or biologically ma-
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Table 1. Screening tests for PMDs and oral cavity cancer (Continued)
lignant; only a small percent-
age of leukoplakias are pro-
gressive or become malignant;
COE cannot distinguish be-
tween those that are or are
not; some precancerous lesions
may exist within oral mucosa
that appears clinically normal
by COE alone (Lingen 2008).
Vital rinsing (e.g. Toluidine
Blue, Tolonium chloride).
Vital rinsing refers to the use of
dyes such as Toluidine Blue or
Tolonium chloride to stain oral
mucosa tissues for PMD orma-
lignancy (Leston 2010; Lingen
2008; Patton 2008). The pro-
cedure is as follows.
• Pre-rinse with acetic acid
• Rinse with water
• Apply Toluidine Blue
• Post-rinse with acetic acid
• Rinse with water
• Observe mucosa to check
for staining.
The result of the test is classified
as positive if tissue is stained and
negative if no tissue is stained,
or equivocal if no definitive re-
sult can be obtained
Advantages: ability to define
areas that could bemalignant or
abnormal but cannot be seen;
assess the extent of the PMDfor
excision.
Disadvantages: benign inflam-
matory lesions subject to stain;
failure of some cancerous le-
sions to stain; variation in
test performance depending on
how thorough the test proce-
dures are followed; contraindi-
cated in those who are known
to be allergic to iodine
Light-based detection (e.g.
ViziLite and ViziLite plus, Mi-
crolux/DL, VELscope, Identafi
3000)
Light-based systems to iden-
tify premalignant and malig-
nant lesions and to highlight
their presence through tissue re-
flectance (Leston 2010; Lingen
2008; Patton 2008). E.g. us-
ing ViziLite Plus or Microlux/
DL, the procedure is as follows
(Lingen 2008).
• Pre-rinse with acetic acid
• Use blue-light light
source to visually assess the
oral cavity.
ViziLite Plus also provides
a tolonium chloride solution
(TBlue) to aid in the marking
of the lesion for biopsy once the
light source is removed
The result of the test is classed
as negative if the appearance of
the epithelium is lightly bluish
white and positive if the appear-
ance of the epithelium is dis-
tinctly white (acetowhite)
Advantages: simple to use;
non-invasive; do not require
consumable reagents; provide
real time results; can be per-
formed by a wide range of op-
erators after a short training pe-
riod.
Disadvantages: the necessity of
a dark environment; high ini-
tial set up (for VELscope) or
recurrent costs (for ViziLite in
low income countries); lack of
permanent record unless pho-
tographed; inability to objec-
tively measure visualisation re-
sults
Blood and saliva analysis. These novel technologies are
at an early stage of develop-
ment and evaluation. Analy-
sis of blood or saliva samples
which tests for the presence of
Cut-off probabilities
vary widely and are dependent
on the individual biomarker or
combination of biomarkers ex-
amined.
Advantages: non-invasive
(saliva tests) or minimally inva-
sive (blood tests).
Disadvantages: there is a ten-
dency for the estimated diag-
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Table 1. Screening tests for PMDs and oral cavity cancer (Continued)
bio-markers of PMD and oral
cancer (Brinkmann 2011; Lee
2009; Li 2006).
Molecular markers for diagno-
sis include changes in cellu-
lar DNA, altered mRNA tran-
scripts, altered protein levels
nostic accuracy of new health
technologies to decline over
time as evidence from inde-
pendent evaluations accumu-
late (Wyatt 1995). This bias,
which can be substantial, has
been demonstrated in other do-
mains, e.g. acute abdominal
pain (Liu 2006) and clinical
decision support systems (Garg
2005). Promising biomarker
tests in several clinical areas
were eventually been shown
to be disappointing (Buchen
2011). It remains to be seen
whether this is the case with oral
cancer and PMDs
PMDs = potentially malignant disorders.
Table 2. Indicators for the assessment of methodological quality
Domain Patient selection Index test Reference standard Flow and timing
Description. Describe methods of pa-
tient selection.
Describe included
patients (characteristics,
prior testing, presenta-
tion, intended use of in-
dex test and setting).
Describe the index test
(s) and how it was con-
ducted and interpreted.
Describe the sequence of
tests, any training or cal-
ibration of assessors (lev-
els of agreement should
be reported. Where this
is measured by the kappa
statistic, acceptable val-
ues
range from 0.61 (mod-
erate agreement) to 1.
00 (almost perfect agree-
ment) (Landis 1977)),
any procedures taken to
ensure blinding of ex-
aminers, post-hoc or a
priori threshold specifi-
cation, any conflict of
interest or commercial
funding
Describe the reference
standard and how it
was conducted and in-
terpreted. Any measures
taken to ensure assessors
were blinded to the re-
sults of the index tests
should be documented,
along with the sequence
of reference and index
tests
Describe the character-
istics and proportion of
patients who did not
receive the index test
(s) and/or reference stan-
dard, who received a
reference standard other
than examination and
clinical evaluation by a
specialist physician, or
who were excluded from
the 2 x 2 table (refer
to flow diagram). De-
scribe the time inter-
val and any interven-
tions between index test
(s) and reference stan-
dard. The length of time
between the index test
and reference standard
should be short in the
majority of cases. If the
period elapsed between
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Table 2. Indicators for the assessment of methodological quality (Continued)
initial screening and ref-
erence standard (exami-
nation and clinical eval-
uation) is greater than 6
weeks then this will be
considered an unaccept-
able delay
Signalling questions
(Yes/No/Unclear).
Was a consecutive or ran-
dom sample of patients
enrolled?
Classify as Yes if consec-
utive patients or a ran-
dom sample of individu-
als were recruited
Classify as No if non-
consecutive patients or
a non-random sample
of individuals were re-
cruited
Classify asUnclear if pa-
tient selection was not
clearly described.
Was calibration of exam-
iners undertaken and re-
sults reported?
Classify as Yes if the ex-
aminers participated in
dedicated training and
calibration was reported
to an acceptable standard
Classify as No if the ex-
aminers did not partici-
pate in dedicated train-
ing or was not assessed,
or training was under-
taken but calibrationwas
not to an acceptable
standard
Classify asUnclear if the
information on training
and calibration was not
stated
Is the reference standard
likely to correctly clas-
sify the target condition?
The reference standard
is an examination and
clinical evaluation by a
physician with special-
ist knowledge which if
stated as such should be
acceptable. Ideally this
should be undertaken
independently by more
than one specialist. Al-
ternatively an acceptable
reference standard is ex-
tended follow-up
Classify as Yes if the test
result is independently
confirmed by at least two
specialists
Classify as No if the test
result is not indepen-
dently confirmed by at
least two specialists or
there was lack of agree-
ment between specialists
Classify asUnclear if the
study does not state who
confirmed the results.
Was there an appropri-
ate time interval between
the index test(s) and ref-
erence standard?
Classify as Yes if the
delay between the in-
dex test(s) and reference
standard is considered
acceptable for themajor-
ity of participants
Classify asNo if the delay
between the index test(s)
and reference standard is
considered unacceptable
for the majority of par-
ticipants
Classify asUnclear if the
delay between the in-
dex test(s) and reference
standard is not explicitly
stated
Did the study avoid in-
appropriate exclusions?
Classify as Yes if the sam-
ple consisted of appar-
ently healthy individu-
als.
Classify as No if only
individuals with existing
PMDs were recruited.
Classify as Unclear if ex-
clusions were not clearly
Were the index test re-
sults interpreted without
knowledge of the results
of the reference stan-
dard?
Classify as Yes if inter-
preters of index test re-
sults clearly do not know
results of reference stan-
dard
Classify as No if inter-
Were the reference stan-
dard results interpreted
without knowledge of
the results of the index
test?
Classify as Yes if special-
ists clearly do not know
index test results when
performing the examina-
tion and clinical evalu-
ation or evaluating fol-
Did all patients receive
the same reference stan-
dard?
Classify asYes if the same
reference standard was
used in all participants
Classify asNo if the same
reference standard was
not used in all partici-
pants
Classify as Unclear if it
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Table 2. Indicators for the assessment of methodological quality (Continued)
described. preters of index test re-
sults clearly know results
of reference standard
Classify
as Unclear if study did
not provide any infor-
mation on whether in-
terpreters of index tests
were blinded to reference
standard
low-up data
Classify as No if spe-
cialists clearly know in-
dex test results when per-
forming the examination
and clinical evaluation
or evaluating follow-up
data
Classify
as Unclear if study did
not provide any informa-
tion on whether special-
ists were blinded to the
index test results
is unclear whether differ-
ent reference standards
were used
Where multiple index
tests were used, were the
results of the second in-
dex test interpretedwith-
out knowledge of the re-
sults of the first index
test?
Classify as Yes if index
test results were inter-
preted without knowl-
edge.
Classify as No if the
index test results were
interpreted with knowl-
edge.
Classify as Unclear if it
is unclear whether the re-
sults of the second in-
dex test were interpreted
without knowledge of
the results of the first in-
dex test
Were all patients in-
cluded in the analysis?
Classify as Yes if all pa-
tients were included in
the analysis.
Classify as No if only
some patients were in-
cluded in the analysis.
Classify as Unclear if it
is unclear whether all pa-
tients were included in
the analysis.
If a threshold was used,
was it pre-specified?
Classify as Yes if the
threshold was pre-speci-
fied.
Classify as No if the
threshold was not pre-
specified.
Classify as Unclear if it
is unclear whether the
threshold was pre-speci-
fied.
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Table 2. Indicators for the assessment of methodological quality (Continued)
Were any conflicts of in-
terest stated?
Classify as Yes if the
study declared no con-
flict of interest.
Classify as No if the
study declared a conflict
of interest.
Classify as Unclear if
therewas no information
on conflict of interest.
Risk of bias: High/Low/
Unclear.
Could the selection of
individuals have intro-
duced bias?
Could the conduct or in-
terpretation of the in-
dex test have introduced
bias?
Could the reference stan-
dard, its conduct, or its
interpretation have in-
troduced bias?
Could the patient flow
have introduced bias?
Concerns regard-
ing applicability: High/
Low/Unclear.
Are there concerns that
the included individuals
do not match the review
question?
Are there concerns that
the index test, its con-
duct, or interpretation
differ from the review
question?
Are there concerns that
the target condition as
defined by the reference
standard does not match
the review question?
PMDs = potentially malignant disorders.
A P P E N D I C E S
Appendix 1. MEDLINE via OVID search strategy
1. exp Mouth/
2. Cheek/
3. or/1-2
4. exp Carcinoma, squamous cell/di
5. exp Precancerous conditions/di
6. (tumor$ or tumour$ or cancer$ or carcinoma$ or carcinogen$ or neoplas$ or malignan$ or metasta$ or dysplas$ or lesion$ or
ulcer$).tw,ot.
7. (pre-cancer$ or precancer$ or premalignan$ or precursor$ or “lichen planus” or leukoplakia or “submucous fibrosis” or (actinic
adj2 keratosis) or candidiasis or erythroplakia or erythroplas$ or erythroleukoplakia or hyperplas$ or hyperkeratos$).tw,ot.
8. or/4-7
9. 3 and 8
10. exp Mouth neoplasms/di
11. Lichen Planus, Oral/di
12. Oral submucous fibrosis/di
13. Oral candidiasis/di
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14. ((oral$ or mouth$ or bucca$ or “oral cavit$” or (oral adj mucosa$) or (mouth adj mucosa$) or lip or lips or tongue$ or gingiv$
or palat$ or cheek$ or “intra oral$” or intraoral$ or gum or gums or labial$) adj3 (tumor$ or tumour$ or cancer$ or carcinoma$
or carcinogen$ or neoplas$ or malignan$ or metasta$ or dysplas$ or lesion$ or ulcer$ or pre-cancer$ or precancer$ or premalignan$
or precursor$ or “lichen planus” or leukoplakia or “submucous fibrosis” or (actinic adj2 keratosis) or candidiasis or erythroplakia or
erythroplas$ or erythroleukoplakia or hyperplas$ or hyperkerato$)).tw,ot.
15. or/10-14
16. 9 or 15
17. Cytodiagnosis/
18. Cytological techniques/
19. Cytophotometry/
20. (brush adj3 biops$).tw,ot.
21. (“oral cdx” or oralcdx).tw,ot.
22. (“modified liquid based cytology” or (exfoliat$ adj3 cytolog$)).tw,ot.
23. (brush$ and (cytodiagnosis or cytopathology)).tw,ot.
24. Tolonium chloride/du
25. Coloring agents/du
26. (“tolonium chloride” or “tolu?dine blue” or “tolu?dine b” or tblue or t-blue).tw,ot.
27. (tolu?dine adj6 (dye$ or rins$ or stain$ or wash$)).tw,ot.
28. exp Luminescence/du
29. Fluorescence/
30. Spectrometry, fluorescence/
31. exp Luminescent Agents/du
32. Light/du
33. Tomography, Optical Coherence/
34. (visual$ adj5 (“light emitting diode” or “blue spectrum” or LED or luminous$)).tw,ot.
35. (visuali?ation adj3 adjunct$).tw,ot.
36. (vizilite or microlux$ or orascoptic or velscope).tw,ot.
37. lumenoscop$.tw,ot.
38. ((tumor$ or tumour$ or cancer$ or carcinoma$ or neoplas$ or carcinogen$ or malignan$ or metata$ or lesion$ or ulcer$) adj5
(fluorescen$ or autofluorescen$ or luminescen$ or chemiluminescen$)).tw,ot.
39. (tissue adj3 reflect$).tw,ot.
40. Spectrophotometry/
41. Acetic acid/du
42. (acetic acid adj3 (wash$ or rins$)).tw,ot.
43. acetowhite.tw,ot.
44. Saliva/an, ch
45. Tumor Markers, Biological/an
46. ((“tumo?r marker$” or “neoplas$ marker$”) adj3 (blood or saliva)).tw,ot.
47. ((analy$ or screen$ or test$ or examin$) adj3 (blood or saliva)).tw,ot.
48. Diagnosis, Oral/
49. Mass screening/
50. Physical examination/
51. ((oral$ or mouth$) adj5 (exam$ or histolog$ or check$ or inspect$)).tw,ot.
52. (visual$ adj3 (exam$ or inspect$ or screen$)).tw,ot.
53. or/17-52
54. 16 and 53
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